NANOG as an adverse predictive marker in advanced non-small cell lung cancer treated with platinum-based chemotherapy

Boksoon Chang, Myung Jae Park, Sue In Choi, Kwang Ho In, Chul Hwan Kim, Seung Hyeun Lee

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: NANOG is a master transcription factor that regulates stem cell pluripotency and cellular reprograming. Increased NANOG expression has been associated with poor survival in several human malignancies. However, the clinical significance of NANOG overexpression in lung cancer has been scarcely evaluated. The aim of this study was to investigate whether NANOG levels are associated with clinical outcomes of patients with non-small cell lung cancer (NSCLC) who were treated with platinum-based chemotherapy. Methods: NANOG levels were evaluated immunohistochemically using the histologic score (H-score) in tumor tissues from patients with advanced NSCLC who received platinum-based doublet treatment. We performed survival analyses according to the NANOG levels and evaluated the association between clinicopathological parameters and levels of NANOG. Results: Multivariate analyses using 112 tumor specimens showed that high NANOG levels were independently associated with short progression-free survival (hazard ratio [HR] =3.09, 95% confidence interval [CI]: 2.01-4.76) and with short overall survival (HR =3.00, 95% CI: 1.98-4.54). Similar results were shown in the subgroup analyses for patients with adenocarcinoma and squamous cell carcinoma. NANOG expression was not associated with any clinicopathological parameter such as age, gender, smoking status, stage, differentiation, or histological subtypes. Conclusion: NANOG overexpression was associated with poor response and short overall survival in patients with advanced NSCLC who were treated with platinum-based chemotherapy, suggesting that NANOG could be a potential adverse predictive marker in this setting.

Original languageEnglish
Pages (from-to)4625-4633
Number of pages9
JournalOncoTargets and Therapy
Volume10
DOIs
Publication statusPublished - 2017 Sep 19

Fingerprint

Platinum
Non-Small Cell Lung Carcinoma
Drug Therapy
Survival
Confidence Intervals
Neoplasms
Survival Analysis
Disease-Free Survival
Squamous Cell Carcinoma
Lung Neoplasms
Adenocarcinoma
Transcription Factors
Stem Cells
Multivariate Analysis
Smoking
Cellular Reprogramming
Therapeutics

Keywords

  • Biomarker
  • Cancer stem cell
  • Chemotherapy
  • Lung cancer
  • NANOG
  • Platinum

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

NANOG as an adverse predictive marker in advanced non-small cell lung cancer treated with platinum-based chemotherapy. / Chang, Boksoon; Park, Myung Jae; Choi, Sue In; In, Kwang Ho; Kim, Chul Hwan; Lee, Seung Hyeun.

In: OncoTargets and Therapy, Vol. 10, 19.09.2017, p. 4625-4633.

Research output: Contribution to journalArticle

@article{2d6064a58987481d9b64d6eb9173cba0,
title = "NANOG as an adverse predictive marker in advanced non-small cell lung cancer treated with platinum-based chemotherapy",
abstract = "Purpose: NANOG is a master transcription factor that regulates stem cell pluripotency and cellular reprograming. Increased NANOG expression has been associated with poor survival in several human malignancies. However, the clinical significance of NANOG overexpression in lung cancer has been scarcely evaluated. The aim of this study was to investigate whether NANOG levels are associated with clinical outcomes of patients with non-small cell lung cancer (NSCLC) who were treated with platinum-based chemotherapy. Methods: NANOG levels were evaluated immunohistochemically using the histologic score (H-score) in tumor tissues from patients with advanced NSCLC who received platinum-based doublet treatment. We performed survival analyses according to the NANOG levels and evaluated the association between clinicopathological parameters and levels of NANOG. Results: Multivariate analyses using 112 tumor specimens showed that high NANOG levels were independently associated with short progression-free survival (hazard ratio [HR] =3.09, 95{\%} confidence interval [CI]: 2.01-4.76) and with short overall survival (HR =3.00, 95{\%} CI: 1.98-4.54). Similar results were shown in the subgroup analyses for patients with adenocarcinoma and squamous cell carcinoma. NANOG expression was not associated with any clinicopathological parameter such as age, gender, smoking status, stage, differentiation, or histological subtypes. Conclusion: NANOG overexpression was associated with poor response and short overall survival in patients with advanced NSCLC who were treated with platinum-based chemotherapy, suggesting that NANOG could be a potential adverse predictive marker in this setting.",
keywords = "Biomarker, Cancer stem cell, Chemotherapy, Lung cancer, NANOG, Platinum",
author = "Boksoon Chang and Park, {Myung Jae} and Choi, {Sue In} and In, {Kwang Ho} and Kim, {Chul Hwan} and Lee, {Seung Hyeun}",
year = "2017",
month = "9",
day = "19",
doi = "10.2147/OTT.S144895",
language = "English",
volume = "10",
pages = "4625--4633",
journal = "OncoTargets and Therapy",
issn = "1178-6930",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - NANOG as an adverse predictive marker in advanced non-small cell lung cancer treated with platinum-based chemotherapy

AU - Chang, Boksoon

AU - Park, Myung Jae

AU - Choi, Sue In

AU - In, Kwang Ho

AU - Kim, Chul Hwan

AU - Lee, Seung Hyeun

PY - 2017/9/19

Y1 - 2017/9/19

N2 - Purpose: NANOG is a master transcription factor that regulates stem cell pluripotency and cellular reprograming. Increased NANOG expression has been associated with poor survival in several human malignancies. However, the clinical significance of NANOG overexpression in lung cancer has been scarcely evaluated. The aim of this study was to investigate whether NANOG levels are associated with clinical outcomes of patients with non-small cell lung cancer (NSCLC) who were treated with platinum-based chemotherapy. Methods: NANOG levels were evaluated immunohistochemically using the histologic score (H-score) in tumor tissues from patients with advanced NSCLC who received platinum-based doublet treatment. We performed survival analyses according to the NANOG levels and evaluated the association between clinicopathological parameters and levels of NANOG. Results: Multivariate analyses using 112 tumor specimens showed that high NANOG levels were independently associated with short progression-free survival (hazard ratio [HR] =3.09, 95% confidence interval [CI]: 2.01-4.76) and with short overall survival (HR =3.00, 95% CI: 1.98-4.54). Similar results were shown in the subgroup analyses for patients with adenocarcinoma and squamous cell carcinoma. NANOG expression was not associated with any clinicopathological parameter such as age, gender, smoking status, stage, differentiation, or histological subtypes. Conclusion: NANOG overexpression was associated with poor response and short overall survival in patients with advanced NSCLC who were treated with platinum-based chemotherapy, suggesting that NANOG could be a potential adverse predictive marker in this setting.

AB - Purpose: NANOG is a master transcription factor that regulates stem cell pluripotency and cellular reprograming. Increased NANOG expression has been associated with poor survival in several human malignancies. However, the clinical significance of NANOG overexpression in lung cancer has been scarcely evaluated. The aim of this study was to investigate whether NANOG levels are associated with clinical outcomes of patients with non-small cell lung cancer (NSCLC) who were treated with platinum-based chemotherapy. Methods: NANOG levels were evaluated immunohistochemically using the histologic score (H-score) in tumor tissues from patients with advanced NSCLC who received platinum-based doublet treatment. We performed survival analyses according to the NANOG levels and evaluated the association between clinicopathological parameters and levels of NANOG. Results: Multivariate analyses using 112 tumor specimens showed that high NANOG levels were independently associated with short progression-free survival (hazard ratio [HR] =3.09, 95% confidence interval [CI]: 2.01-4.76) and with short overall survival (HR =3.00, 95% CI: 1.98-4.54). Similar results were shown in the subgroup analyses for patients with adenocarcinoma and squamous cell carcinoma. NANOG expression was not associated with any clinicopathological parameter such as age, gender, smoking status, stage, differentiation, or histological subtypes. Conclusion: NANOG overexpression was associated with poor response and short overall survival in patients with advanced NSCLC who were treated with platinum-based chemotherapy, suggesting that NANOG could be a potential adverse predictive marker in this setting.

KW - Biomarker

KW - Cancer stem cell

KW - Chemotherapy

KW - Lung cancer

KW - NANOG

KW - Platinum

UR - http://www.scopus.com/inward/record.url?scp=85030256195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030256195&partnerID=8YFLogxK

U2 - 10.2147/OTT.S144895

DO - 10.2147/OTT.S144895

M3 - Article

AN - SCOPUS:85030256195

VL - 10

SP - 4625

EP - 4633

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

SN - 1178-6930

ER -